Welcome to our dedicated page for Pelthos Therapeutics SEC filings (Ticker: PTHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pelthos Therapeutics Inc. (PTHS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nevada-incorporated biopharmaceutical company listed on the NYSE American, Pelthos files a range of documents with the U.S. Securities and Exchange Commission that describe its business, governance, and financial obligations.
Key filings include Form 8-K current reports, where Pelthos discloses material events such as financing transactions, product acquisitions, and governance changes. Recent 8-K filings describe a senior secured term loan facility with Horizon Technology Finance Corporation intended to support commercialization of ZELSUVMI and the launches of Xepi and Xeglyze, an asset purchase agreement for the Xeglyze head lice treatment, and a securities purchase agreement for senior secured convertible notes used to fund the acquisition and planned relaunch of Xepi and to accelerate ZELSUVMI commercialization.
Other 8-K items and the company’s definitive proxy statement on Schedule 14A provide detail on board composition, director compensation policies, annual meeting proposals, and shareholder voting results. These documents outline Pelthos’ governance structure, committee responsibilities, and the terms under which directors and executives are compensated and indemnified.
On Stock Titan, investors can review Pelthos’ periodic reports (such as Forms 10-K and 10-Q when filed) for information on revenue from ZELSUVMI, operating expenses, cash position, and risk factors related to its commercial dermatology portfolio and financing arrangements. Form 4 and related insider transaction reports, when available, show equity dealings by directors and officers, offering additional insight into insider alignment.
AI-driven summaries on this page highlight the most important points from lengthy filings, such as covenants in loan agreements, conversion terms in convertible notes, and implications of mergers and name changes. Real-time updates from EDGAR ensure that new Pelthos filings—whether related to financings, acquisitions, or governance—are quickly reflected, while the AI layer helps users understand how each document fits into the company’s broader strategy around ZELSUVMI, Xepi, and Xeglyze.
Pelthos Therapeutics Inc. furnished an update as its CEO prepares to present and hold investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. The accompanying presentation highlights Pelthos as a commercial-stage biopharmaceutical company focused on cutaneous infectious diseases, led by its at-home molluscum treatment ZELSUVMI.
The deck notes that Zelsuvmi launched in July 2025 and has seen strong uptake, with more than 20,000 units dispensed from launch through April 2026, 16,774 prescribed units and 4,867 unique prescribers. As of May 11, 2026, the company lists a stock price of $26.85, approximately $240 million market capitalization and $32.0 million of cash at the end of Q1 2026.
Pelthos also emphasizes recent acquisitions of two FDA-approved dermatology products, XEPI for impetigo and XEGLYZE for head lice, with anticipated commercial launches in early 2027 and mid-2027. Management highlights overlapping prescriber call points, 64 sales territories covering about 53% of molluscum claims, and payer coverage where 70% of combined Medicaid and commercial lives are under one Zelsuvmi contract.
Pelthos Therapeutics Inc.’s Form 4 details equity changes tied to Chief Financial Officer Francis Knuettel II’s separation. A Separation Agreement dated May 15, 2026 governs forfeiture and accelerated vesting of his stock awards.
The filing reports the forfeiture and cancellation of unvested restricted stock units and stock options for no consideration, and the acceleration of vesting for 19,525 RSUs out of 33,472 previously granted under the 2023 Equity Incentive Plan. Certain stock options also became fully vested and exercisable, while others were cancelled.
Separately, the Lara Knuettel Revocable Trust, an entity associated with Mr. Knuettel, sold 1,500 shares of common stock on May 22, 2026 in open-market trades at a weighted average price of $26.8433 per share, leaving 11,316 shares held by the trust and 10,000 shares held by Camden Capital LLC.
Issuer filed a Form 144 reporting proposed affiliate sales of common stock. The notice lists 1,720 shares with an associated figure of $46,629.20 and four trade entries: 650, 550, 170, and 350 shares dated in September 2024. The broker is Fidelity Brokerage Services LLC.
Pelthos Therapeutics Inc. reported two key corporate governance changes. The board’s Audit Committee dismissed CBIZ CPAs P.C. as independent registered public accounting firm and approved the appointment of Grant Thornton LLP for the fiscal year ending December 31, 2026. The company states CBIZ’s prior audit reports for 2024 and 2025 contained no adverse opinions, disclaimers, or qualifications, and there were no disagreements or reportable events through May 18, 2026.
The company also detailed a Separation and Release Agreement with former Chief Financial Officer, Treasurer, and Secretary Francis Knuettel II, whose employment ended April 10, 2026. Under the agreement, he will receive earned but unpaid compensation, reimbursement of business expenses, separation pay equal to 12 months of base salary, or $430,000, and accelerated vesting of certain stock options and RSUs that would have vested in the 12 months after the separation date, subject to the agreement becoming effective after a seven‑day revocation period.
Pelthos Therapeutics Inc. director Ezra M. Friedberg reported a small tax-related share disposition. On May 14, 2026, 144 shares of common stock were disposed of at a weighted average price of $27.007 per share to satisfy estimated tax obligations tied to vesting restricted stock units.
The filing states these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. After this transaction, Friedberg directly holds 81,883 common shares, and he is also the manager of entities that hold 40,000 shares (Key Recovery Group LLC) and 82,072 shares (Balmoral Financial Group LLC), which he may be deemed to beneficially own only to the extent of his pecuniary interest.
Pelthos Therapeutics Inc. amended a Schedule 13G to report that Ikarian Capital, LLC and Neil Shahrestani jointly disclose beneficial ownership of 256,598 shares of common stock, representing 7.7% of the class. The ownership percentage is calculated using 3,355,543 shares outstanding as of March 11, 2026, per the issuer's Form 10-K.
The filing states the shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts, that Ikarian Capital has investment discretion, and that Mr. Shahrestani may be deemed to indirectly beneficially own those securities. The filing includes joint filing language and customary disclaimers about Section 13(d)/13(g) status.
Pelthos Therapeutics Inc. reported first quarter 2026 results that show rapid ZELSUVMI growth but continued losses. Net product revenue for ZELSUVMI reached $10.7 million, up about 17% from $9.1 million in the fourth quarter of 2025, with total revenue of $10.9 million for the quarter.
ZELSUVMI dispensed units increased from 6,312 in the prior quarter to 7,884 in the first quarter of 2026, a 25% rise, and cumulative ZELSUVMI net sales since its July 2025 launch reached $26.9 million. The company expanded its sales force to 64 territory managers to support commercialization.
Pelthos remains unprofitable, posting a net loss of $10.2 million and Adjusted EBITDA of negative $8.0 million for the quarter. Cash and cash equivalents were $32.0 million as of March 31, 2026, supported by a $50.0 million senior secured term loan facility, of which $30.0 million was drawn in January 2026.
Pelthos Therapeutics Inc. reported its first meaningful commercial quarter, with total revenue of $10.9 million for the three months ended March 31, 2026, driven mainly by ZELSUVMI product sales of $10.7 million. Operating expenses rose to $24.0 million, leading to a net loss of $10.2 million compared with a $2.0 million loss a year earlier.
Cash, cash equivalents and restricted cash increased to $32.2 million, helped by net proceeds of $29.3 million from a new venture loan and security agreement, partly offset by $13.1 million of cash used in operating activities. Total assets were $145.4 million and stockholders’ equity was $35.1 million, reflecting substantial intangible assets and goodwill from recent acquisitions and the LNHC merger.
Pelthos Therapeutics Amendment No. 2 updates beneficial ownership for 3i, 3i Management LLC and Maier Joshua Tarlow, reporting beneficial ownership of 337,026 shares, representing 9.99% of common stock based on 3,355,543 shares outstanding as of March 11, 2026.
The disclosed position comprises 318,933 common shares plus up to 18,093 shares issuable upon conversion of 800 shares of Series A Convertible Preferred Stock and a senior secured convertible note (original principal $1,000,000), each conversion subject to a 9.99% beneficial-ownership blocker. Mr. Tarlow has shared voting and dispositive power via management and partnership structures.
Pelthos Therapeutics Inc. Chief Financial Officer John M. Gay has filed an initial ownership report showing equity-based compensation holdings. He holds 30,518 restricted stock units (RSUs), each representing one share of common stock, granted on July 2, 2025 under the company’s 2023 Equity Incentive Plan.
The RSUs vest with one-third on July 2, 2026 and the remainder in equal quarterly installments over the following two years, contingent on continued service. He also holds stock options to purchase 93,000 shares of common stock at an exercise price of $13.50 per share, granted on July 2, 2025, with the same one-third initial vesting on July 2, 2026 and the balance vesting quarterly over two years.